MEASuRE: Metreleptin Effectiveness and Safety Registry
What is the goal of the study?
This is a registry study with the following objectives: To estimate the incidence rate of major safety events, including fatal or necrotizing pancreatitis, hepatic adverse events, severe hypoglycemia, serious hypersensitivity reaction, serious infections resulting in hospitalization or death, new diagnoses of autoimmune disorders (for instance, autoimmune hepatitis, lomerulonephritis, lupus, erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis), autoimmune disease exacerbation, all cancers (excluding non-melanoma skin cancer) by cancer type, exposed pregnancies and pregnancy outcomes, and all deaths (including causes of death) in patients treated with metreleptin as part of current clinical practice.
Who can participate in the study?
Please contact the study team listed below to learn more.